A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer (Q27008869)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer	scientific article

Statements

scholarly article

1 reference

1 reference

15 October 2020

systematic review

1 reference

comparative study

1 reference

A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer (English)

0 references

breast neoplasm

1 reference

15 October 2020

1 reference

7 November 2019

aromatase inhibitor

1 reference

17 November 2019

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

hormonal antineoplastic agent

1 reference

15 October 2020

systematic review

1 reference

based on heuristic

inferred from title

object named as

Paula Rochon

3

0 references

author name string

Ava A. John-Baptiste

1

1 reference

Wei Wu

2

1 reference

Geoffrey M. Anderson

4

1 reference

Chaim M. Bell

5

1 reference

language of work or name

1 reference

publication date

2013

1 reference

6 May 2013

7 references

13 March 2019

3 April 2019

17 June 2019

2 October 2019

7 November 2019

17 November 2019

15 October 2020

8 references

13 March 2019

3 April 2019

17 June 2019

2 October 2019

7 November 2019

17 November 2019

15 October 2020

8

1 reference

e62614

1 reference

5

1 reference

copyright license

Creative Commons Attribution 4.0 International

7 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

7 November 2019

Europe PubMed Central

17 November 2019

Europe PubMed Central

15 October 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Bending the Cost Curve in Cancer Care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

21 March 2017

When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

21 March 2017

Bias in published cost effectiveness studies: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

21 March 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

7 April 2017

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

A glimpse into the black box of cost-effectiveness analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Sensitivity analysis in cost-effectiveness studies: from guidelines to practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Modeling in pharmacoeconomic studies: funding sources and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Meta-analysis: excess mortality after hip fracture among older women and men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Intergroup Exemestane Study mature analysis: overall survival data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Hormonal therapies for early breast cancer: systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Using value of information analysis to inform publicly funded research priorities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Preference-based measures in economic evaluation in health care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

The quality of reporting in published cost-utility analyses, 1976-1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Utility approach to measuring health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 September 2017

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

31 May 2018

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

31 May 2018

Handling uncertainty in economic evaluations of healthcare interventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

31 May 2018

Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Industry sponsored bias in cost effectiveness analyses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Delivering affordable cancer care in high-income countries

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062614

21 January 2018

Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 November 2018

Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 November 2018

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646035

28 November 2018

Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subgroups and heterogeneity in cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23671612

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0062614

0 references

2013PLoSO...862614J

0 references

1 reference

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27008869&oldid=1731596631"